PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|September 23, 2014
Almac Group Appoints Two Marketing Directors
Author(s)Pharmaceutical Technology Editors
Almac Group recently appointed two key positions in marketing: Market Development Director, and Senior Market Insight Director.
Advertisement
Almac Group, a pharmaceutical contract development and manufacturing organization, has created two new positions to expand their global marketing team.
Matt Cocking has been appointed market development director for the Clinical Technologies business unit. This position was created to help develop the marketing plan to keep in line with the company’s business strategy. Cocking comes from the clinical trial software solutions company, Y Prime, with over 10 years of experience as a senior marketing leader.
Laura Montgomery will also be joining the Almac Group as the senior market insight director. Montgomery will be responsible for developing, delivering, and communicating actionable market research to assist Almac Group in making data-driven decisions. Montgomery was previously the project director for a healthcare market research consultancy, Adelphi Research.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement